Novel Anti-cancer Agents and Their Mechanisms of Action

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 2151

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacology & Chemical Biology, Baylor College of Medicine, Baylor Plaza, Houston, TX 77030, USA
Interests: small-molecule drug discovery; medicinal chemistry; proteolysis-targeting chimeras (PROTACs); targeted protein degradation (TPD); chemical biology; CNS drug discovery
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmacology & Chemical Biology, Baylor College of Medicine, Baylor Plaza, Houston, TX 77030, USA
Interests: small-molecule drug discovery; medicinal chemistry; proteolysis-targeting chimeras (PROTACs); targeted protein degradation (TPD); chemical biology; cheminformatics; synthetic organic chemistry

Special Issue Information

Dear Colleagues,

Despite social and technological progress, cancer remains a major concern and a leading cause of human suffering. Every year, there is an increase in the number of cases and deaths due to the ongoing danger posed by the majority of cancers. The alarming rise in incidence of new types of cancer and the public burden represents a real crisis for public health and healthcare systems worldwide. The comprehensive exploration of pathways responsible for, as well as mechanisms and structures of, anticancer chemical entities have significantly contributed in cancer prevention and treatment. The determination of different tumor cell lines, followed by the assessment of the impact of many natural and synthetic anticancer compounds, has resulted in remarkable success. However, major challenges remain, which in the current therapy is the toxicity may be attributed to the use of anticancer agents and the normal tissue damage caused as a consequence. There is a dire need to devise potential anticancer agents with fewer off-target effects. The scope of the present Issue includes novel anticancer compounds from synthetic and natural sources, validated in vitro or in vivo via assessments of their mechanism of actions, or new potential therapeutic strategies for cancer treatment such as proteolysis-targeting chimeras (PROTACs) and combinatorial chemotherapy. It is our pleasure to invite authors to submit original research articles and review articles focused on “Novel Anti-Cancer Agents and Their Mechanisms of Action”.

Dr. Chandra Bhushan Mishra
Dr. Mohd Abdullaha
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • novel anticancer agents
  • mechanism of action
  • synthetic and natural compounds
  • PROTACs
  • combinatorial chemotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 1922 KiB  
Article
Synthesis and Biological Evaluation of Benzo [4,5]- and Naphtho[2′,1′:4,5]imidazo[1,2-c]pyrimidinone Derivatives
by Polina Kamzeeva, Nikolai Dagaev, Sofia Lizunova, Yuri Khodarovich, Anna Sogomonyan, Anastasia Kolchanova, Vadim Pokrovsky, Vera Alferova, Alexey Chistov, Artur Eshtukov-Shcheglov, Elizaveta Eshtukova-Shcheglova, Evgeny Belyaev, Dmitry Skvortsov, Anna Varizhuk and Andrey Aralov
Biomolecules 2023, 13(11), 1669; https://doi.org/10.3390/biom13111669 - 20 Nov 2023
Viewed by 1520
Abstract
Azacarbazoles have attracted significant interest due to their valuable properties, such as anti-pathogenic and antitumor activity. In this study, a series of structurally related tricyclic benzo[4,5]- and tertacyclic naphtho[2′,1′:4,5]imidazo[1,2-c]pyrimidinone derivatives with one or two positively charged tethers were synthesized and evaluated for anti-proliferative [...] Read more.
Azacarbazoles have attracted significant interest due to their valuable properties, such as anti-pathogenic and antitumor activity. In this study, a series of structurally related tricyclic benzo[4,5]- and tertacyclic naphtho[2′,1′:4,5]imidazo[1,2-c]pyrimidinone derivatives with one or two positively charged tethers were synthesized and evaluated for anti-proliferative activity. Lead tetracyclic derivative 5b with two amino-bearing arms inhibited the metabolic activity of A549 lung adenocarcinoma cells with a CC50 value of 3.6 μM, with remarkable selectivity (SI = 17.3) over VA13 immortalized fibroblasts. Cell-cycle assays revealed that 5b triggers G2/M arrest without signs of apoptosis. A study of its interaction with various DNA G4s and duplexes followed by dual luciferase and intercalator displacement assays suggests that intercalation, rather than the modulation of G4-regulated oncogene expression, might contribute to the observed activity. Finally, a water-soluble salt of 5b was shown to cause no acute toxic effects, changes in mice behavior, or any decrease in body weight after a 72 h treatment at concentrations up to 20 mg/kg. Thus, 5b is a promising candidate for studies in vivo; however, further investigations are needed to elucidate its molecular target(s). Full article
(This article belongs to the Special Issue Novel Anti-cancer Agents and Their Mechanisms of Action)
Show Figures

Figure 1

Back to TopTop